Objective measurement of pain and dyspnea

Powered by our novel AI-derived biomarkers from a wearable sensor array also capturing heart rate, respiratory rate, and SpO₂.

400+

Clinical Patients

>90%

Accuracy

Clinical Studies

Pain

Dyspnea

SpO₂

Message Clinic

Daily Health Screening

The Problem

Pain management today is subjective and inefficient

50M+

Americans Impacted

Pain impacts more than 50 million Americans annually, costing over $750 billion per year.

Reason for Doctor Visit

Pain is the number one reason people visit a physician.

70%

ED Visits

Up to 70% of Emergency Department visits involve pain, yet no objective tools exist to assess it accurately.

"Inadequate assessment and treatment of pain has become a public health issue"

— Institute of Medicine, Relieving Pain in America

Clinically Validated Technology

Proven results across multiple clinical studies

Published Research

Multiple published studies with leading research institutes including Stanford University

400+

Patients

Validated across 400+ patients in clinical studies

Clinical Studies

Rigorous clinical validation across five comprehensive studies

Our Publications

Brain activity monitoring and cerebral hemodynamic research

2018

Journal of Pain Research Peer-Reviewed

Correlation of Changes in Hemodynamic Response as Measured by Cerebral Optical Spectrometry with Subjective Pain Ratings

A prospective cohort study evaluating cerebral optical spectrometry in volunteers and laboring women, demonstrating significant correlation with subjective pain ratings.

Medical monitoring technology and infrared spectroscopy

2022

MDPI IJERPH Open Access

Pain Assessment Using Near-Infrared Spectroscopy

Comprehensive research on utilizing near-infrared spectroscopy technology for objective pain assessment in clinical and research settings.

Latest News

Recent achievements and milestones

Featured

Featured in Nature Magazine

"How a 'pain-o-meter' could improve treatments" — Nature, September 2024

September 2024

Funding

>$2M Grant Funding

Secured major funding from federal agencies including NSF and FDA to advance objective pain measurement technology

2024

Why CereVu?

Leading the future of objective pain assessment

Real-Time and Continuous Monitoring

Non-invasive assessment using near-infrared spectroscopy for immediate, ongoing clinical insights.

AI-Driven Accuracy

Proprietary algorithms translate cerebral oxygenation changes into personalized pain indices.

Clinically Validated

Over 400 patients across 5 published studies with >90% accuracy in pain assessment.